Simplexa Direct Amplification Disc Kit, Product Kit Code MOL1455
FDA Device Recall #Z-0457-2022 — Class II — November 19, 2021
Recall Summary
| Recall Number | Z-0457-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | November 19, 2021 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | DiaSorin Molecular LLC |
| Location | Cypress, CA |
| Product Type | Devices |
| Quantity | 29495 kits |
Product Description
Simplexa Direct Amplification Disc Kit, Product Kit Code MOL1455
Reason for Recall
A subset of affected discs are at risk of leakage when it is used more than one time with Simplexa COVID-19 Direct and/or Simplexa Flu A/B & RSV Direct Gen II. Leakage from a well that had a positive sample may cause further cross-contamination in areas of the lab if not properly cleaned.
Distribution Pattern
US: AZ, CA, CO, CT, DC, FL, GA, HI, IA, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, NC, ND, NE, NH, NJ, NM, NV, NY, OH, PA, RI, SC, SD, TN, TX, VA, VT, WA, WI, WV; and Worldwide: Kuwait, Australia, Israel, Italy, Canada, Chile, Puerto Rico, United Arab Emirates.
Lot / Code Information
Kit Product Code MOL1455 (UDI 01-30816101025092) contains 3 discs with Disc Product Code MOL1452. Below lists the MOL1455 Kit Lot numbers (and MOL1452 Disc Lot Numbers): 12410N (12152N), 12411N (12147N), 12413N (12149N), 12477N (12150N), 12602N (11548NA), 12603N (12144N), 12721N (12148N), 12889N (12151N), 13369N (12817N), 13370N (13151N), 13434N (12382N), 13652N (12835N), and 13242N (12154N)*. *Kit Lot #13242N (Disc Lot #12154N) was shipped to Europe and not within the US.
Other Recalls from DiaSorin Molecular LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2153-2023 | Class II | Simplexa Direct Amplification Disc Kit, Rx Only... | Jun 14, 2023 |
| Z-1209-2023 | Class II | Simplexa COVID-19 Direct, REF: MOL4150; includi... | Jan 30, 2023 |
| Z-1210-2023 | Class II | Simplexa Flu A/B & RSV Direct Gen II, REF: MOL2... | Jan 30, 2023 |
| Z-0162-2022 | Class II | SIMPLEXA COVID-19 Positive Control Pack, REF MO... | Sep 23, 2021 |
| Z-2549-2020 | Class II | MOL3655 Simplexa VZV Swab Direct - Product Usag... | May 12, 2020 |
Frequently Asked Questions
Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately — you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.